Apoptosis and apoptosis-based therapy in lung cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 9, 2009, Pages 952-957

  Xu, Cheng Xiong ^a   Jin, Hua ^b   Cho, Myung Haing ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c Seoul National University   (South Korea)

Author keywords

Anticancer agent; Apoptosis; Lung cancer

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; AEG 35156; AMG 655; ANTISENSE OLIGONUCLEOTIDE; APOMAB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; MAPATUMUMAB; MONOCLONAL ANTIBODY; OBLIMERSEN; PACLITAXEL; PANITUMUMAB; PEMETREXED; PROTEIN BCL 2; PROTEIN INHIBITOR; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CLINICAL TRIAL; DRUG DESIGN; DRUG SENSITIVITY; GENE MUTATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NONHUMAN; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; SMALL CELL CARCINOMA; TUMOR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; LUNG NEOPLASMS;

EID: 73449145964     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009789377682     Document Type: Review

References (86)

1. Sun, Y.; Peng, Z.L. Programmed cell death and cancer. Postgrad. Med. J., 2009, 85(1001), 134-140.
2. Call, J.A.; Eckhardt, S.G.; Camidge, D.R. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol., 2008, 9(10), 1002-1011.
3. Reed, J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol., 1999, 17(9), 2941-53.
4. Schulze-Bergkamen, H.; Krammer, P.H. Apoptosis in cancer - implications for therapy. Semin. Oncol., 2004, 31(1), 190-119.
5. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer, 2002, 2(6), 420-430.
6. Riedl, S.J.; Shi, Y. Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol., 2004, 5(11), 897-907.
7. Shivapurkar, N.; Reddy, J.; Chaudhary, P.M.; Gazdar, A.F. Apoptosis and lung cancer, a review. J. Cell Biochem., 2003, 88(5), 885-898.
8. Fesik, S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer, 2005, 5(11), 876-885.
9. Nagata, S. Apoptosis by death factor. Cell, 1997, 88(3), 355-365.
10. Herbst, R.S.; Heymach, J.V.; Lippman, S.M. Lung cancer. N. Engl. J. Med., 2008, 359(13), 1367-1380.
11. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA. Cancer J. Clin., 2008, 58(2), 71-96.
12. Travis, W.D.; Travis, L.B.; Devesa, S.S. Lung cancer. Cancer, 1995, 75(1 Suppl), 191-202.
13. Joseph, B.; Ekedahl, J.; Sirzen, F.; Lewensohn, R.; Zhivotovsky, B. Differences in expression of pro-caspases in small cell and nonsmall cell lung carcinoma. Biochem. Biophys. Res. Commun., 1999, 262(2), 381-387.
14. Joseph, B.; Lewensohn, R.; Zhivotovsky, B. Role of apoptosis in the response of lung carcinomas to anti-cancer treatment. Ann. N Y. Acad. Sci., 2000, 926, 204-216.
15. Feinstein-Rotkopf, Y.; Arama, E. Can't live without them, can live with them, roles of caspases during vital cellular processes. Apoptosis, 2009, 14(8), 980-985.
16. Budihardjo, I.; Oliver, H.; Lutter, M.; Luo, X.; Wang, X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol., 1999, 15, 269-290.
17. Hersey, P.; Zhang, X.D. How melanoma cells evade trail-induced apoptosis. Nat. Rev. Cancer, 2001, 1(2), 142-150.
18. Slee, E.A.; Adrain, C.; Martin, S.J. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J. Biol. Chem., 2001, 276(10), 7320-7326.
19. Sirzen, F.; Zhivotovsky, B.; Nilsson, A.; Bergh, J.; Lewensohn, R. Higher spontaneous apoptotic index in small cell compared with non-small cell lung carcinoma cell lines; lack of correlation with Bcl-2/Bax. Lung Cancer, 1998, 22(1), 1-13.
20. Cummings, J.; Ward, T.H.; Ranson, M.; Dive, C. Apoptosis pathway-targeted drugs-from the bench to the clinic. Biochim. Biophys. Acta, 2004, 1705(1), 53-66.
21. Tamm, I.; Kornblau, S.M.; Segall, H.; Krajewski, S.; Welsh, K.; Kitada, S.; Scudiero, D.A.; Tudor, G.; Qui, Y.H.; Monks, A.; Andreeff, M.; Reed, J.C. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res., 2000, 6(5), 1796-1803.
22. Tamm, I.; Wang. Y.; Sausville, E.; Scudiero, D.A.; Vigna, N.; Oltersdorf, T.; Reed, J.C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res., 1998, 58(23), 5315-5320.
23. Monzo, M.; Rosell, R.; Felip, E.; Astudillo, J.; Sanchez, J.J.; Maestre, J.; Martin, C.; Font, A.; Barnadas, A.; Abad, A. A novel anti-apoptosis gene, Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol., 1999, 17(7), 2100-2104.
24. Nicholson, D.W. From bench to clinic with apoptosis-based therapeutic agents. Nature, 2000, 407(6805), 810-816.
25. Adams, J.M.; Cory, S. The Bcl-2 protein family, arbiters of cell survival. Science, 1998, 281(5381), 1322-1326.
26. Reed, J.C. Bcl-2 family proteins. Oncogene, 1998, 17(25), 3225-3236.
27. Cory, S.; Adams, J.M. The Bcl2 family, regulators of the cellular life-or-death switch. Nat. Rev. Cancer, 2002, 2(9), 647-656.
28. Zamzami, N.; Kroemer, G. The mitochondrion in apoptosis, how Pandora's box opens. Nat. Rev. Mol. Cell Biol., 2001, 2(1), 67-71.
29. Martinou, J.C.; Green, D.R. Breaking the mitochondrial barrier. Nat. Rev. Mol. Cell Biol., 2001, 2(1), 63-67.
30. Wei, M.C.; Zong, W.X.; Cheng, E.H.; Lindsten, T.; Panoutsakopoulou, V.; Ross, A.J.; Roth, K.A.; MacGregor, G.R.; Thompson, C.B.; Korsmeyer, S.J. Proapoptotic BAX and BAK, a requisite gateway to mitochondrial dysfunction and death. Science, 2001, 292(5517), 727-730.
31. Uren, R.T.; Dewson, G.; Chen, L.; Coyne, S.C.; Huang, D.C.; Adams, J.M.; Kluck, R.M. Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. J. Cell Biol., 2007, 177(2), 277-287.
32. Maitra, A.; Amirkhan, R.H.; Saboorian, M.H.; Frawley, W.H.; Ashfaq, R. Survival in small cell lung carcinoma is independent of Bcl-2 expression. Hum. Pathol., 1999, 30(6), 712-717.
33. Caputi, M.; Groeger, A.M.; Esposito, V.; De Luca, A.; Murabito, M.; Tahir, T.; Giordano, G.G.; Baldi, F.; Giordano, A.; Wolner, E. Frequent high expression of bax pro-apoptotic protein in non-small cell lung cancer. Anticancer Res., 1999, 19(1B), 825-827.
34. Huang, C.; Kohno, N.; Inufusa, H.; Kodama, K.; Taki, T.; Miyake, M. Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53. Am. J. Pathol., 1999, 155(3), 955-965.
35. Brambilla, E.; Gazzeri, S.; Lantuejoul, S.; Coll, J.L.; Moro, D.; Negoescu, A.; Brambilla, C. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin. Cancer Res., 1998, 4(7), 1609-1618.
36. Sengupta, S.; Harris, C.C. p53, traffic cop at the crossroads of DNA repair and recombination. Nat. Rev. Mol. Cell Biol., 2005, 6(1), 44-55.
37. Toloza, E.M. Gene therapy for lung cancer. Semin. Thorac. Cardiovasc. Surg., 2005, 17(3), 205-212.
38. Vousden, K.H. Activation of the p53 tumor suppressor protein. Biochim. Biophys. Acta, 2002, 1602(1), 47-59.
39. Vousden, K.H.; Lu, X. Live or let die, the cell's response to p53. Nat. Rev. Cancer, 2002, 2(8), 594-604.
40. Moroni, M.C.; Hickman, E.S.; Lazzerini Denchi, E.; Caprara, G.; Colli, E.; Cecconi, F.; Muller, H.; Helin, K. Apaf-1 is a transcriptional target for E2F and p53. Nat. Cell Biol., 2001, 3(6), 552-558.
41. Miyashita, T.; Reed, J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 1995, 80(2), 293-299.
42. Owen-Schaub, L.B.; Zhang, W.; Cusack, J.C.; Angelo, L.S.; Santee, S.M.; Fujiwara, T.; Roth, J.A.; Deisseroth, A.B.; Zhang, W.W.; Kruzel, E.; Radisky, R. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell Biol., 1995, 15(6), 3032-3040.
43. Wu, G.S.; Burns, T.F.; McDonald, E.R. 3rd.; Jiang, W.; Meng, R.; Krantz, I.D.; Kao, G.; Gan, D.D.; Zhou, J.Y.; Muschel, R.; Hamilton, S.R.; Spinner, N.B.; Markowitz, S.; Wu, G.; el-Deiry, W.S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet., 1997, 17(2), 141-143.
44. Subramanian, J.; Govindan, R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol., 2008, 9(7), 676-682.
45. Vahakangas, K.H.; Bennett, W.P.; Castren, K.; Welsh, J.A.; Khan, M.A.; Blomeke, B.; Alavanja, M.C.; Harris, C.C. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res., 2001, 61(11), 4350-4356.
46. Smith, L.E.; Denissenko, M.F.; Bennett, W.P.; Li, H.; Amin, S.; Tang, M.; Pfeifer, G.P. Targeting of lung cancer mutational hot-spots by polycyclic aromatic hydrocarbons. J. Natl. Cancer Inst., 2000, 92(10), 803-811.
47. Hernandez-Boussard, T.M.; Hainaut, P. A specific spectrum of p53 mutations in lung cancer from smokers, review of mutations compiled in the IARC p53 database. Environ. Health Perspect., 1998, 106(7), 385-391.
48. Hainaut, P.; Pfeifer, G.P. Patterns of p53 G - >T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis, 2001, 22(3), 367-374.
49. Greulich, H.; Chen, T.H.; Feng, W.; Janne, P.A.; Alvarez, J.V.; Zappaterra, M.; Bulmer, S.E.; Frank, D.A.; Hahn, W.C.; Sellers, W.R.; Meyerson, M. Oncogenic transformation by inhibitorsensitive and -resistant EGFR mutants. PLoS Med., 2005, 2(11), e313.
50. Ji, H.; Li, D.; Chen, L.; Shimamura, T.; Kobayashi, S.; McNamara, K.; Mahmood, U.; Mitchell, A.; Sun, Y.; Al-Hashem, R.; Chirieac, L.R.; Padera, R.; Bronson, R.T.; Kim, W.; Janne, P.A.; Shapiro, G.I.; Tenen, D.; Johnson, B.E.; Weissleder, R.; Sharpless, N.E.; Wong, K.K. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell, 2006, 9(6), 485-495.
51. Politi, K.; Zakowski, M.F.; Fan, P.D.; Schonfeld, E.A.; Pao, W.; Varmus, H.E. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev., 2006, 20(11), 1496-1510.
52. Pao, W.; Miller, V.A. Epidermal growth factor receptor mutations. small-molecule kinase inhibitors and non-small-cell lung cancer, current knowledge and future directions. J. Clin. Oncol., 2005, 23(11), 2556-2568.
53. Ciardiello, F.; Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med., 2008, 358(11), 1160-1174.
54. Kim, E.S.; Hirsh, V.; Mok, T.; Socinski, M.A.; Gervais, R.; Wu, Y.L.; Li, L.Y.; Watkins, C.L.; Sellers, M.V.; Lowe, E.S.; Sun, Y.; Liao, M.L.; Osterlind, K.; Reck, M.; Armour, A.A. ;Shepherd, F.A.; Lippman, S.M.; Douillard, J.Y. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST), a randomised phase III trial. Lancet, 2008, 372(9652), 1809-1818.
55. Shigematsu, H.; Gazdar, A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer, 2006, 118(2), 257-262.
56. West, K.A.; Linnoila, I.R.; Belinsky, S.A.; Harris, C.C.; Dennis, P.A. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3′-kinase/Akt pathway in vitro and in vivo. Cancer Res., 2004, 64(2), 446-451.
57. Stambolic, V. Mak, T.W. Woodgett, J.R. Modulation of cellular apoptotic potential, contributions to oncogenesis. Oncogene, 1999, 18(45), 6094-6103.
58. Datta, S.R.; Brunet, A.; Greenberg, M.E. Cellular survival, a play in three Akts. Genes Dev., 1999, 13(22), 2905-2927.
59. Sun, S.; Schiller, J.H.; Gazdar, A.F. Lung cancer in never smokers - a different disease. Nat. Rev. Cancer, 2007, 7(10), 778-790.
60. Ohmori, T.; Podack, E.R.; Nishio, K.; Takahashi, M.; Miyahara, Y.; Takeda, Y.; Kubota, N.; Funayama, Y.; Ogasawara, H.; Ohira, T.; Ohta, S.; Sajio, A. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC. CPT-11. ADM) is inhibited by bcl-2. Biochem. Biophys. Res. Commun., 1993, 192(1), 30-36.
61. Koty, P.P.; Zhang, H.; Levitt, M.L. Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer, 1999, 23(2), 115-127.
62. Storey, S. Targeting apoptosis, selected anticancer strategies. Nat. Rev. Drug Discov., 2008, 7(12), 971-972.
63. Shoemaker, A.R.; Mitten, M.J.; Adickes, J.; Ackler, S.; Refici, M.; Ferguson, D.; Oleksijew, A.; O'Connor, J.M.; Wang, B.; Frost, D.J.; Bauch, J.; Marsh, K.; Tahir, S.K.; Yang, X.; Tse, C.; Fesik, S.W.; Rosenberg, S.H.; Elmore, S.W. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin. Cancer Res., 2008, 14(11), 3268-3277.
64. Nakahara, T.; Takeuchi, M.; Kinoyama, I.; Minematsu, T.; Shirasuna, K.; Matsuhisa, A.; Kita, A.; Tominaga, F.; Yamanaka, K.; Kudoh, M.; Sasamata, M. YM155, a novel small-molecule survivin suppressant. induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res., 2007, 67(17), 8014-8021.
65. Iwasa, T.; Okamoto, I.; Suzuki, M.; Nakahara, T.; Yamanaka, K.; Hatashita, E.; Yamada, Y.; Fukuoka, M.; Ono, K.; Nakagawa, K. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant. in non-small cell lung cancer cell lines. Clin. Cancer Res., 2008, 14(20), 6496-6504.
66. Farmer, G. Targeted lung cancer therapies. Nat. Rev. Drug Discov., 2004, 3(7), 547-548.
67. de Fougerolles, A.; Vornlocher, H.P.; Maraganore, J.; Lieberman, J. Interfering with disease, a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov., 2007, 6(6), 443-453.
68. Klasa, R.J.; Gillum, A.M.; Klem, R.E.; Frankel, S.R. Oblimersen Bcl-2 antisense, facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev., 2002, 12(3), 193-213.
69. Taylor, J.K.; Zhang, Q.Q.; Wyatt, J.R.; Dean, N.M. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol., 1999, 17(11), 1097-1100.
70. LaCasse, E.C.; Cherton-Horvat, G.G.; Hewitt, K.E.; Jerome, L.J.; Morris, S.J.; Kandimalla, E.R.; Yu, D.; Wang, H.; Wang, W.; Zhang, R.; Agrawal, S.; Gillard, J.W.; Durkin, J.P. Preclinical characterization of AEG35156/GEM 640. a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin. Cancer Res., 2006,12(17), 5231-5241.
71. Putt, K.S.; Chen, G.W.; Pearson, J.M.; Sandhorst, J.S.; Hoagland, M.S.; Kwon, J.T.; Hwang, S.K.; Jin, H.; Churchwell, M.I.; Cho, M.H.; Doerge, D.R.; Helferich, W.G.; Hergenrother, P.J. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat. Chem. Biol., 2006, 2(10), 543-550.
72. Humphreys, R.C.; Halpern, W. Trail receptors, targets for cancer therapy. Adv. Exp. Med. Biol., 2008, 615, 127-158.
73. Luster, TA.; Carrell, J.A.; McCormick, K.; Sun, D.; Humphreys, R. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol. Cancer Ther., 2009, 8(2), 292-302.
74. Pukac, L.; Kanakaraj, P.; Humphreys, R.; Alderson, R.; Bloom, M.; Sung, C.; Riccobene, T.; Johnson, R.; Fiscella, M.; Mahoney, A.; Carrell, J.; Boyd, E.; Yao, X.T.; Zhang, L.; Zhong, L.; von Kerczek, A.; Shepard, L;. Vaughan, T.; Edwards, B.; Dobson, C.; Salcedo, T.; Albert, V. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody. induces cell death in multiple tumour types in vitro and in vivo. Br. J. Cancer, 2005, 92(8), 1430-1441.
75. Voortman, J.; Resende, T.P.; Abou, E.l.; Hassan, M.A. ;Giaccone, G.; Kruyt, F.A. TRAIL therapy in non-small cell lung cancer cells, sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol. Cancer Ther., 2007, 6(7), 2103-2112.
76. Cai, D.W.; Mukhopadhyay, T.; Liu, Y.; Fujiwara, T.; Roth, J.A. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum. Gene Ther., 1993, 4(5), 617-624.
77. Hlobilkova, A.; Knillova, J.; Svachova, M.; Skypalova, P.; Krystof, V.; Kolar, Z. Tumour suppressor PTEN regulates cell cycle and protein kinase B/Akt pathway in breast cancer cells. Anticancer Res., 2006, 26(2A), 1015-1022.
78. LA1 mice. Cancer Gene Ther., 2008, 15(5), 275-283.
79. Jin, H.; Kim, T.H.; Hwang, S.K.; Chang, S.H.; Kim, H.W.; Anderson, H.K.; Lee, H.W.; Lee, K.H.; Colburn, N.H.; Yang, H.S.; Cho, M.H.; Cho, C.S. Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis. cell cycle. and angiogenesis in lungs of K-ras null mice. Mol. Cancer Ther., 2006, 5(4), 1041-1049.
80. Hwang, S.K.; Jin, H.; Kwon, J.T.; Chang, S.H.; Kim, T.H.; Cho, C.S.; Lee, K.H.; Young, M.R.; Colburn, N.H.; Beck, G.R. Jr.; Yang, H.S.; Cho, M.H. Aerosol-delivered programmed cell death 4 enhanced apoptosis. controlled cell cycle and suppressed AP-1 activity in the lungs of AP-1 luciferase reporter mice. Gene Ther., 2007, 14(18), 1353-1361.
81. Mizushima, N. Autophagy, process and function. Genes Dev., 2007, 21(22), 2861-73.
82. Mathew, R.; Karantza-Wadsworth, V.; White, E. Role of autophagy in cancer. Nat. Rev. Cancer, 2007, 7(12), 961-967.
83. Lum, J.J.; Bauer, D.E.; Kong, M.; Harris, M.H.; Li, C.; Lindsten T.; Thompson, C.B. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell, 2005, 120(2), 237-248.
84. Amaravadi, R.K.; Thompson, C.B. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin. Cancer Res., 2007, 13(24), 7271-7279.
85. Amaravadi, R.K.; Yu, D.; Lum, J.J.; Bui, T.; Christophorou, M.A.; Evan, G.I. Thomas-Tikhonenko, A. Thompson, C.B. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J. Clin. Invest., 2007, 117(2), 326-336.
86. Zangemeister-Wittke, U.; Hopkins-Donaldson, S. Apoptosis regulation and drug resistance in malignant pleural mesothelioma. Lung Cancer, 2005, 49 (Suppl 1), S105-S108.